The adenine nucleotide translocator: a new potential chemotherapeutic target

Anne-Sophie Belzacq1, Catherine Brenner

  • 1Centre National de la Recherche Scientifique, UMR 6022, Université de Technologie de Compiègne, 60205 Compiègne, France.

Current Drug Targets
|October 11, 2003
PubMed

Insights

Identifying new drug targets is crucial for apoptosis modulation. The adenine nucleotide translocator (ANT) protein is a key target, influencing cell death through its pore-forming activity and interaction with cancer genes.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Apoptosis (programmed cell death) is a critical biological process.
  • Mitochondrial membrane permeabilization is a central event in many cell death pathways.
  • Identifying novel therapeutic targets for apoptosis modulation is essential for drug development.

Purpose of the Study:

  • To review the role of the adenine nucleotide translocator (ANT) as a therapeutic target in apoptosis.
  • To explore how various chemotherapeutic agents modulate ANT's pro-apoptotic function.
  • To provide insights into the therapeutic modulation of apoptosis.

Main Methods:

  • Review of molecular and pharmacological studies on ANT.
  • Analysis of ANT's bi-functional role: nucleotide exchange and pore formation.
  • Examination of ANT's regulation by Bax/Bcl-2 family proteins.
  • Investigation of direct modulation of ANT pore activity by diverse agents.

Main Results:

  • The adenine nucleotide translocator (ANT) is a validated therapeutic target due to its dual function.
  • ANT mediates ADP/ATP exchange and contributes to cell death via pore formation.
  • ANT's function is regulated by oncogenes and directly modulated by chemotherapeutic agents, pro-oxidants, and other molecules.

Conclusions:

  • ANT's critical role in apoptosis makes it a promising target for drug development.
  • Understanding how chemotherapeutics target ANT's pro-apoptotic function offers therapeutic strategies.
  • Modulating ANT activity presents a viable approach for developing novel apoptosis-modulating drugs.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
ABC Transporters: Importer01:27

ABC Transporters: Importer

ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types: